Ning Cheng

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer

STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer

The association of continuity of care and risk of mortality in breast cancer patients with cardiometabolic comorbidities

Immune receptor inhibition through enforced phosphatase recruitment

Expression of ubiquitin‑conjugating enzyme E2T in colorectal cancers and clinical implications

Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

Authors' Reply to Courtney Suggs and Colleagues’ Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”

Physicians’ Perceived Awareness of Patients’ Medications: A Cross-Sectional Survey

Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs

Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications